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Correspondence First Experience in Humans Using
Adipose Tissue–Derived Regenerative
Cells in the Treatment of Patients With
ST-Segment Elevation Myocardial InfarctionTo the Editor: In preclinical animal models of acute myocardial
infarction (AMI), administration of freshly isolated adipose tissue–
derived regenerative cells (ADRCs) immediately after the AMI
improved left ventricular (LV) function and myocardial perfusion
(1,2). The predominant working mechanism of ADRC therapy in
AMI is believed to be through paracrine release of antiapoptotic,
immunomodulatory, and proangiogenic factors. These factors
evoke cardiomyocyte salvage and stimulate neoangiogenesis in the
infarct border zone and eventually result in reduced infarct scar
formation and adverse cardiac remodeling (1–3). ADRCs com-
prise, among other cells, immune-competent cells, endothelial
progenitor cells, and mesenchymal stem cells. The amount of these
mesenchymal stem cells in freshly isolated adipose tissue digestates
is 2,500-fold greater than that of freshly aspirated bone marrow,
which makes cell culture unnecessary to generate therapeutically
sufficient cells (4). On average, 20 to 40 million cells can be
isolated and prepared within 2 h after liposuction from as little as
200 g of lipoaspirate, enabling the treatment of AMI patients
within hours after the primary percutaneous coronary intervention
(PPCI).
The APOLLO trial is a randomized, double-blind, placebo-
controlled, phase I/IIa study (NCT00442806) designed to assess
the safety and feasibility of intracoronary infusion of ADRCs in
the treatment of patients in the acute phase of a large ST-segment
elevation acute myocardial infarction (STEMI). Patients were
eligible for enrollment if interventional treatment for their AMI
was successful, they had no history of heart disease, and the area of
LV hypo- or akinesia corresponded to the culprit lesion. The
residual LV ejection fraction (LVEF) needed to be between 30%
and 50% as measured by transthoracic echocardiography after the
PPCI. After informed consent, the patients underwent a liposuc-
tion procedure of the periumbilical region, after which ADRCs
were isolated using the Cytori Celution device (Cytori Therapeu-
tics Inc., San Diego, California). Within 24 h after the PPCI, the
ADRCs were infused intracoronarily, while carefully monitoring
for coronary flow–related side effects. The main safety endpoints
were defined as the change in coronary flow (pre- vs. post-
infusion), the occurrence of an major adverse cardiovascular and
cerebrovascular event (MACCE) or severe adverse event (SAE), or
hospitalization due to congestive heart failure during the 6-month
follow-up. Feasibility endpoints were defined as the change in
LVEF, infarct size as determined by delayed enhancement-cardiac
magnetic resonance imaging, and perfusion defect as assessed by
sestamibi-single-photon emission computed tomography (MIBI-
SPECT) (visual rest score).
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vA total of 14 patients presenting with an anterior wall AMI
were enrolled in the trial and randomized 3:1 to receive an
intracoronary infusion of either 20 million ADRCs (n  10) or
placebo solution (n  4) in the culprit artery (see Table 1 for
baseline demographics). One patient in the treatment group was
omitted from analysis due to the inadvertent use of an inappro-
priate cell strainer, resulting in 9 analyzable patients. The liposuc-
tion procedure was well tolerated in all patients, although in 2
patients, a significant bleeding event occurred. After these 2
bleeding events, a protocol amendment that regulated strict control
of heparin use after the PPCI and excluded the use of glycoprotein
IIb/IIIa inhibitors resulted in no more serious bleeding events in
the remaining 10 patients. Intracoronary infusion of, on average,
17.4  4.1 million ADRCs was successful and well tolerated in all
patients and did not result in any coronary flow impediment as
measured by coronary angiography and coronary flow reserve. One
patient in the cell treatment group experienced a target lesion
revascularization as opposed to none in the control group (p 
NS). SAEs occurred in 2 of 4 patients (50%) in the placebo group
and 3 of 9 patients (33%) in the ADRC group (p  NS).
Importantly, no unanticipated adverse effects related to the ADRC
therapy were reported.
MIBI-SPECT analysis demonstrated a 4% improvement in
global LVEF in ADRC-treated patients from 52.1% to 56.1%,
whereas the placebo group deteriorated by 1.7% (52.0% to
Demographics and Baseline Characteristics*Table 1 Demographics and Baseline Characteristics*
Placebo
(n  4)
ADRCs
(n  9)
Age, yrs 55 7.5 61 2.1
Male, % 100 78
White, % 100 100
Body mass index, kg/m2 27.6 3.3 27.5 3.0
Smoking, % 50.0 66.7
Hypertension, % 50.0 66.7
Creatine kinase-myocardial band, mol/l 92.0 5.7 78.0 3.9
NT-proBNP, pmol/l 225 116 250 86
Left ventricular ejection fraction, %
2-dimensional echocardiography
(at screening)
43.5 3.3 46.1 2.5
Cardiac magnetic resonance imaging 47.9 5.4 52.4 4.8
MIBI-SPECT 52.0 10.0 52.1 2.5
Infarct size, % of left ventricle 24.7 9.2 31.6 5.3
Perfusion defect, %, VRS 15.0 4.9 16.9 2.1
*Only includes per treatment assessable patients.
ADRC  adipose tissue–derived regenerative cell; MIBI-SPECT  sestamibi single photon-
mission computed tomography; NT-proBNP: N-terminal pro–B-type natriuretic peptide; VRS 
isual rest score.
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groups of5.7% (p 0.114). A similar positive trend of improved
cardiac function was found by CMR analysis, which demonstrated
a 4.6% improvement of global LVEF in the ADRC-treated
group from baseline to 6-month follow-up (p  0.091). The
percentage of the left ventricle infarcted was reduced by 52%
(31.6  5.3 % to 15.3  2.6% at 6-month follow-up, p  0.002;
Fig. 1A) in the ADRC-treated patients, as opposed to no change
in the placebo-treated AMI patients (24.7  9.2 % vs. 24.7 
4.1%; p  0.48 for difference between groups). In addition, in the
placebo group, the perfusion defect deteriorated by1.8% (15.0
4.9% to 16.8 4.3%) compared with a significant improvement of
the perfusion defect in ADRC-treated patients from 16.9  2.1%
to 10.9  2.4% at 6-month follow-up (change of 6.0%, p 
0.004; Fig. 1B; p  0.23 for difference between groups).
The main findings of the APOLLO trial at the 6-month
Figure 1 Infarct Size and Perfusion Defect in APOLLO Patients
(A) The percentage of the left ventricle (LV) infarcted improved significantly in
adipose tissue–derived regenerative cell (ADRC)–treated patients from baseline
(open column) to the 6-month follow-up time point (solid column; example to
the right, red arrows depict infarct at baseline [upper right panel] and
6-month follow-up [lower right panel]), with no improvement in placebo
patients. (B) A significant improvement of the perfusion defect was seen in
ADRC-treated patients (example to the right, red arrows) from baseline (open
column) to the 6-month follow-up time point (solid column) compared with a
deterioration in placebo patients.clinical and angiographic follow-up time point are 1) liposuction toharvest ADRCs in the acute phase of an AMI is safe and feasible;
2) intracoronary infusion of freshly isolated ADRCs was safe and
did not result in an alteration of coronary flow or any indication of
microvascular obstruction; 3) no SAEs were related to the ADRC
therapy; and 4) ADRC infusion resulted in a trend toward
improved cardiac function, accompanied by a significant improve-
ment of the perfusion defect and a 50% reduction of myocardial
scar formation. The latter is consistent with findings in preclinical
studies and concordant with the presumed proangiogenic, antiapo-
ptotic, and immunomodulatory working mechanism of ADRC
therapy.
The ongoing ADVANCE study is a multicenter, prospective,
randomized, placebo-controlled phase IIb/III clinical trial that will
assess the safety and efficacy of an intracoronary infusion of 2 doses
of ADRC in up to 375 patients with an STEMI. This study was
initiated in May 2011.
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